Physicians

Department / Division
Medicine / Medicine - Cardiology

Address
DUMC 3850
Durham, NC 27710

2400 Pratt Street, Room 0311 Terrace Level
Durham, NC 27750

Appointment Telephone
919-681-5816

Office Telephone
919-668-8845

Fax Telephone
919-668-7059

Training

• MD, University of Washington School of Medicine, 1989

Residency

• Internal Medicine, University of Arizona Health Sciences Center, Tucson VA Medical Center, 1989-1993
• Cardiology, Duke University Medical Center, 1993-1996

Clinical Interests
Acute coronary care, acute myocardial infarction, unstable angina, congestive heart failure

Research Interests
Dr. Mahaffey is also a faculty member of the Duke Clinical Research Institute (DCRI) and co-Director of Cardiovascular Research. His primary research focus is the design and conduct of multicenter clinical trails and analyses of important clinical cardiac issues using large patient databases.  His research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies.

Dr. Mahaffey is also interested in the methodology of clinical trials.  Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events, and the conduct of large multinational clinical trials.  The DCRI CEC and CV Mega-Trial groups are internationally recognized leaders and have developed efficient strategies to adjudicate clinical endpoints and conduct and manage operational features of global cardiovascular clinical trials.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Adolor Corporation
• Amgen, Inc.
• AstraZeneca
• Bayer
• Biotronik
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo Co., Ltd
• Elsevier
• Exeter
• Forest Research Institute
• Genentech, Inc (Roche Holding)
• Gilead Sciences, Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Lilly (Eli Lilly)
• Medtronic Inc.
• Merck Sharpe & Dohme (Merck & Co, USA)
• Novartis
• Orexigen Therapeutics, Inc.
• Ortho-McNeil Pharmceutical (Johnson & Johnson)
• Pfizer Inc.
• Polymedix Inc
• Sanofi-Aventis
• St. Jude Medical, Inc.
• WebMD/Medscape

Representative Publications
4. Mahaffey KW, Harrington RA, Simoons ML, Granger CB, Graffagnino C, Alberts MJ, Laskowitz DT, Miller JM, Sloan MA, Berdan LG, MacAulay6 CM, Lincoff AM, Deckers, J, Topol EJ, Califf RM for the PURSUIT Investigators. Stroke in patients with acute coronary syndromes: Incidence and outcomes in the PURSUIT trial. Circulation 1999;99:2371-2377. (1999)

Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casa AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB for the AMISTAD Investiators. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo controlled trial. The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) Trial. J Am Col Cardiol 1999;34:1711-1720. (1999)

3. Mahaffey KW, Granger CB, Sloan MA, Thompson T, Gore JM, Weaver WD, White HD, Simoons ML, Barbash GI, Topol EJ, Califf RM for the GUSTO-I Investigators. Risk factors for in-hospital non-hemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: Results from GUSTO-I. Circulation 1998/97:757-764. (1998)

2. Mahaffey KW, granger CB, Toth CA, White HD, Stebbins AL, Barbash GI, Vahanian A, Topol EJ, Califf RM for the GUSTO-I Investigators. Diabetic retinopathy should not be a contraindication for thrombolytic therapy for acute myocardial infarction: Review of ocular hemorrhage incidence and location in the GUSTO-I trial. J AM Coll Cardiol 1997;30:1606-1610. (1997)

1. Mahaffey KW, Granger CB, Collins R, O'Connor CM, Ohman EM, Bleich SD, Col JJ, Califf RM. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1995;77:551-556. (1995)